Skip to content
OpenCapital
Get started

Bioventus BVS Concentration Risk %

Concentration Risk % at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
93.1%-5.3pp
Heartland Express logo
Heartland ExpressHTLD
32%+6.0pp
Enovix Corporation logo
Enovix CorporationENVX
83%+36.0pp
Weis Markets logo
Weis MarketsWMK
100%0.0pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
36%+7.0pp
Strattec Security logo
Strattec SecuritySTRT
0.5%0.0pp

Segments

By product

See full
Product A36%+16.1%
Product C20%+11.1%
Product B15%+15.4%
Product D7%0.0%
Product E6%-14.3%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×